- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Evolocumab has no negative impact on cognitive function among paediatric patients with FH
PCSK9 inhibition with evolocumab reduces low-density lipoprotein cholesterol in adults and children with familial hypercholesterolaemia (FH). The HAUSER-RCT found that 24 weeks of treatment did not impact cognitive function in children.
Evolocumab treatment did not affect cognitive functions like learning, psychomotor function, executive function and attention, says Dr Raul D Santos, MD, PhD, in a recent study published in The European Journal of Preventive Cardiology.
HAUSER-OLE was an 80-week open-label extension of HAUSER-RCT. This randomized, double-blind, 24-week trial evaluated the efficacy and safety of evolocumab in children aged 10 to 17 years with FH. All patients received monthly subcutaneous injections of 420 mg of evolocumab. Psychomotor function, attention, visual learning, and executive function tests were administered at baseline and weeks 24 and 80 of the OLE. Descriptive analysis and ANCOVA analyzed changes over time, and Cohen’s d statistic was employed to determine the magnitude of treatment effects.
Key findings from the study are:
- ANCOVA results indicated no decrease in performance across visits during 80 weeks of evolocumab treatment for a computerized battery of cognitive tests, including Groton Maze Learning (executive function), One Card Learning accuracy (visual learning), Identification speed (visual attention), or Detection speed (psychomotor function).
- Performance on all tasks was similar for those who received placebo or evolocumab in the RCT.
- For all tests, the least square mean differences between patients taking placebo vs evolocumab were trivial (parent study).
In this study, they tested whether treating children with evolocumab for 80 weeks affected their mental ability to perform several tasks. A battery of tests showed no decrease in performance across visits during 80 weeks of evolocumab treatment.
Reference:
Raul D Santos et al. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment, European Journal of Preventive Cardiology, 2023; zwad332, https://doi.org/10.1093/eurjpc/zwad332
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751